OPB 31121

Drug Profile

OPB 31121

Alternative Names: OPB-31121

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Hepatocellular carcinoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 30 Sep 2015 Discontinued - Phase-I for Cancers in South Korea, USA, Japan & Hong Kong (PO)
  • 30 Sep 2015 Discontinued - Phase-I/II for Hepatocellular carcinoma in Japan (PO)
  • 21 Sep 2015 No recent reports on development identified - Phase-I for Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top